HIGHLIGHTS
- who: Omar Alhalabi from the The University of Texas MD Anderson Cancer Center, Houston, TX, USA have published the Article: MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers, in the Journal: NATURE COMMUNICATIONS NATURE COMMUNICATIONS
- what: The authors evaluated the clinical outcomes of patients with UC who were treated with pemetrexed stratified by tumor MTAP protein expression as a surrogate marker for 9p21 status. To optimize the clinical utility of the findings , the authors aim to investigate MTAP among a combination of biomarkers that have been associated with responsiveness to . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.